Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

GLYC


Fundamental

Company: Crescent Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -15.35
Insider Own: 28.91%
Shs Outstand: 27.56M
Perf Week: 27.84%
Market Cap: 534.05M
Forward P/E: -
EPS next Y: -3.47
Insider Trans: 20.59%
Shs Float: 19.59M
Perf Month: 71.05%
Enterprise Value: 326.50M
PEG: -
EPS next Q: -0.88
Inst Own: 72.37%
Short Float: 7.39%
Perf Quarter: 74.91%
Income: -141.14M
P/S: 49.27
EPS this Y: 71.72%
Inst Trans: 44.96%
Short Ratio: 7.09
Perf Half Y: 61.10%
Sales: 10.84M
P/B: 2.68
EPS next Y Percentage: 4.31%
ROA: -112.29%
Short Interest: 1.45M
Perf YTD: 63.41%
Book/sh: 7.22
P/C: 2.51
EPS next 5Y: 31.70%
ROE: -135.50%
52W High: 28.77 -32.64%
Perf Year: 7.67%
Cash/sh: 7.74
P/FCF: -
EPS past 3/5Y: 45.01% 33.26%
ROIC: -69.11%
52W Low: 8.72 122.25%
Perf 3Y: -84.74%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: 424.86% 1.31%
Gross Margin: 99.23%
Volatility W: 11.85%
Volatility M: 10.78%
Perf 5Y: -93.77%
Dividend TTM: -
EV/Sales: 30.12
EPS Y/Y TTM: 73.87%
Oper. Margin: -1298.47%
ATR (14): 1.42
Perf 10Y: -96.92%
Dividend Ex-Date: -
Quick Ratio: 6.56
Sales Y/Y TTM: -100.00%
Profit Margin: -1301.53%
RSI (14): 81.09
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 6.56
EPS Q/Q: 59.10%
SMA20: 44.22%
Beta: 1.13
Target Price: 28.33
Payout: -
Debt/Eq: 0.01
Sales Q/Q: -
SMA50: 64.15%
Rel Volume: 1.20
Prev Close: 19.40
Employees: 44
LT Debt/Eq: 0.01
Earnings: Feb 26 BMO
SMA200: 52.03%
Avg Volume: 204.09K
Price: 19.38
IPO: Jan 10, 2014
Option/Short: No / Yes
EPS/Sales Surpr.: -62.25% 8.44%
Trades:
Volume: 245,017
Change: -0.10%

Technical:


Latest News:

Glycobiology/Glycomics Market 2024 Growth Parameters – Thermo Fisher Scientific, Agilent ... somewhat bullish
TMO A EW WAT BRKR SIAL 7986JP PROZ DHR 7701JP

Summary: A new research report titled Global Glycobiology/Glycomics Market provides an in-depth analysis of a global market summarizing key uses, growth analysis, industry trends, and forecasts to 2032. The report offers a detailed picture of the current industrial situation incorporating authentic and anticipated market estimates in terms of value and volume. The report also includes a full analysis of raw material sourcing, significant suppliers, raw material price patterns, and an examination of the industrial chain.

Full article
2024-09-19T05:48:31Z
Capital One Financial Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC) somewhat bearish
GLYC

Summary: Capital One Financial issued Q1 2024 EPS estimates for GlycoMimetics with a 'Equal Weight' rating. The consensus estimate for GlycoMimetics' full-year earnings is ($0.54) per share. Several brokerages commented on GLYC, with StockNews.com downgrading it and HC Wainwright maintaining a 'neutral' rating.

Full article
2024-05-09T10:51:04Z
Dow Launches Bio-Circular and Circular Propylene Glycol Solutions in North America somewhat bullish
DOW

Summary: Dow (NYSE: DOW) launches two new sustainable varieties of propylene glycol solutions in North America, featuring bio-circular and circular feedstocks, aiming to offer high-performance products with sustainability benefits.

Full article
2024-05-07T17:18:24Z